FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML
The drug has been approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
FDA Approvals
source https://www.medscape.com/viewarticle/984907?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/984907?src=rss
Comments
Post a Comment